Chairman and Managing Director Glenn Saldanha said on Monday that the company has several assets under development, including ...

MiNK Therapeutics surged on tumor remission data for agenT-797, but financial risks and limited clinical proof remain. Learn ...

Avalon GloboCare Corp (NASDAQ:ALBT) saw its stock jump 16% following the announcement that it has been granted a standard ...

Investing.com -- Avalon GloboCare Corp (NASDAQ: ALBT) stock surged 16% after the precision diagnostic consumer products developer announced it has secured a new standard patent from the Hong Kong ...

Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced the issuance of a new standard patent by the Hong Kong ...

The authors proposed two hypotheses: first, that methamphetamine induces neuroinflammation, and second, that it alters neuronal stem cell differentiation. These are valuable hypotheses, and the ...

MiNK Therapeutics surged 730% on breakthrough testicular cancer data with agenT-797. Click here to read my analysis on INKT ...

Allogeneic cell therapies are advancing in clinical trials, requiring oncologists and pathologists to understand the ...

MiNK Therapeutics shares jumped as new clinical data show durable remission in testicular cancer and tumor reduction in ...

New report adds to growing evidence of iNKT cell therapy’s potential in solid tumorsNEW YORK, July 11, 2025 (GLOBE NEWSWIRE) ...

MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced the ...

Research led by Naval Medical University's Changzheng Hospital in China reports that an off-the-shelf cell therapy built from ...